Detail akcie ADOCIA online

Business Summary: Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Adocia SA revenues decreased 78% to EUR1.6M. Net loss applicable to common stockholders totaled EUR9.4M vs. income of EUR4.3M. Revenues reflect Research and collaborative agreements decrease of 97% to EUR161K, Licencing revenues decrease of 40% to EUR1.5M. Net loss reflects Other Operating Income/Expenses decrease from EUR11.2M (income) to EUR0K, Research tax credit decrease of 43% to EUR1.8M (income).